期刊文献+

凡德他尼治疗甲状腺髓样癌研究进展 被引量:4

原文传递
导出
摘要 甲状腺髓样癌(MTC)是起源于甲状腺C细胞或滤泡旁细胞的肿瘤,约占甲状腺恶性肿瘤的5%~10%,其恶性程度介于乳头状癌和未分化癌之间,属中等恶性肿瘤.女性患者居多,具有局部浸润生长及较早出现血道淋巴道转移的特征.在临床上分为遗传性髓样癌和散发型髓样癌两种[1].临床以手术治疗为主,尤其是直径2 cm以上的MTC,虽无明显可见的淋巴结,但隐匿性淋巴结转移率可高达50%,因此,目前多主张扩大手术范围.对于晚期MTC,单靠手术难以彻底清除肿瘤.因其起源于甲状腺滤泡旁细胞,与正常甲状腺滤泡细胞相比,无法摄取碘,所以放射性131I治疗效果不佳.而传统的放疗、化疗被作为中晚期MTC无有效控制手段时的姑息治疗方法[2].2011年FDA批准的新药凡德他尼为甲状腺髓样癌的治疗提供了新武器.关键词:凡德他尼;表皮生长因子受体;血管内皮生长因子受体;甲状腺髓样癌;非细胞肺癌分类号:R979
作者 饶志方
机构地区 华润武钢总医院
出处 《中国药师》 CAS 2014年第7期1217-1220,共4页 China Pharmacist
  • 相关文献

参考文献5

二级参考文献105

  • 1HAZARD J B, HAWK W K, CRILE G Jr. Medullary (solid) carcinoma of the thyroid-a clinicopathologic entity[J]. Journal of Clinical Endocrinology and Metabolism, 1959, 19(1): 152-161.
  • 2JUNG J, UCHINO S, LEE Y, et al. A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline muta- tion[J]. Journal of Korean Medidal Science, 2010, 25(2): 226-229.
  • 3FRIEDELL G H, CAREY R J, RQSEN H. Familial thyroid cancer[J]. Cancer, 1962, 15(2): 241-245.
  • 4NORMANN T. Medullary thyroid carcinoma in Norway[J]. Acta Pathologica Microbiologica Scandinavica Section A Patholo-gy, 1977, 85(6): 775-786.
  • 5RAUE F, FRANK-RAUE K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management[J]. Hormones(Athens), 2009, 8(1): 23-28.
  • 6KOUVARAKI M A, SHAPIRO S E, PERRIER N D, et al. RET proto-oncogene: a review and update of genotype-pheno- type correlation in hereditary medullary thyroid cancer and as- sociated endocrine tumors[J]. Thyroid, 2005, 15(6): 531-544.
  • 7SAKORAFAS G H, FRIESS H, PEROS G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of pro- phylactic thyroidectomy[J]. Endocrine-Related Cancer, 2008, 15(4): 871-884.
  • 8MOLINE J, ENG C. Multiple endocrine neoplasia type 2: an overview[J]. Genetics in Medicine, 2011, 13(9): 755-764.
  • 9TAKAHASHI M, RITZ J, COOPER G M. Activation of a novel human transforming gene, ret, by DNA rearrangement[J]. Cell, 1985, 42(2): 581-588.
  • 10TAKAHASHI M, BUMA Y, IWAMOTO T, et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains[J]. Oncogene, 1988, 3(5): 571-578.

共引文献20

同被引文献64

  • 1柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报(医学版),2011,31(10):1470-1474. 被引量:3
  • 2高再荣,安锐,张永学,Hans J.Biersack.核素靶向治疗在转移性甲状腺髓样癌治疗中的价值[J].中华肿瘤杂志,2006,28(8):621-624. 被引量:8
  • 3Jemal A1 ,Siegel R ,Ward E ,et al. Cancer statistics ,2009[J]. CA Cancer J Clin, 2009,59 (4) : 225-249.
  • 4Kojic KL, Kojic SL, Wiseman SM. Differentiated thyroid cancers : a com- prehensive review of novel targeted therapies[J]. Expert Rev Anticancer Ther,2012,12(3) : 345-357.
  • 5Henderson YC, Shellenberger TD,Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma[J]. Clin Cancer Res ,2009,15 (2) :485-49l.
  • 6Salajegheh A, Smith RA, Kasem K, et al. Single nueleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes[J]. Eur J Surg Oneol, 2011,37 (1) :93-99.
  • 7Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A [J]. Endocr Relat Cancer,2006,13(4) : 1173-1183.
  • 8Xing M. Genetic Aherations in the Phosphatidylinositol-3 Kinase/Akt Path- way in Thyroid Cancer[J]. Thyroid, 2010,20 (7) : 697-706.
  • 9Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer[J].Nat Rev Endocrinol, 2011,7 (10) : 569-580.
  • 10Druker BJ,Tamura S, Buchdunger E,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells[J]. Nat Med, 1996,2(5) :561-566.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部